Identifying the window of aggressive postpartum breast cancer based on the 21-gene Oncotype DX® test in women with HR+, HER2-negative breast cancer

By afschroeder • July 2, 2026

Zhang S, Queen KJ, Duggirala N, Yang E, Lipsyc-Sharf M, Racz J, Bennett J, Hong K, Suresh Y, Hamilton C, Pitta M, Chien N, La E, Russell CA, Bardia A, Kapoor NS. Identifying the window of aggressive postpartum breast cancer based on the 21-gene Oncotype DX® test in women with HR+, HER2-negative breast cancer. NPJ Breast Cancer. 2026 Jul 1. doi: 10.1038/s41523-026-01002-2. Epub ahead of print. PMID: 42386766.

Tags: Fellow, Hematology/Oncology, Post Doc, Publications

American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults

O'Dwyer K, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer J, Hayes-Lattin[...]

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

Choueiri TK, Merchan J, Patnaik A, Drakaki A, Rini BI, Rha SY, Lee JL, Ornstein MC, Kumar R, Hwang C, Shao Y, Park SH, Barata[...]

Optimizing a Hematology/Oncology Curriculum for Internal Medicine Residents: A Two-Institution Modified Delphi Study

Silverstein JF, Huppert LA, Schwede M, Goglin S, Johnson TP, Babik JM, Brondfield S. Optimizing a Hematology/Oncology Curriculum for Internal Medicine Residents: A Two-Institution Modified[...]